Abstract
ABSTRACT The aim of present study was to develop mesoporous silica nanoparticles that have a combination of therapeutic and diagnostic functionalities (theranostics), with the ultimate goal ofcreating smart nanocarriers the therapeutic actions of which are controlled by diagnostic information. Folic acid conjugation was carried out to prevent premature release of cargo and to achieve the goal of targeted therapy. The mesoporous silica was made to absorb gemcitabine hydrochloride, a BCS Class III drug, using a wetness impregnation method. Physicochemical characterization of the preparation was carried out using infrared spectroscopy, particle size analysis, transmission electron microscopy, drug uptake study and fluorescence microscopy. The particle size of Mesoporous silica nanoparticles i.e, SBA-15 was found to be 564.5 nm. The average pore diameter was found to be of 49.88 nm, and the surface area was 120.031 m2/g. The drug-loaded SBA-15 exhibited 47.3% drug release within 10 hours in phosphate buffer of pH 7.4.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
